Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.55%89.141.3%$797.85m
AMGNAmgen Inc.
1.08%187.501.2%$644.97m
GILDGilead Sciences, Inc.
0.29%65.740.9%$476.37m
BIIBBiogen Inc.
1.30%325.331.3%$432.61m
ILMNIllumina, Inc.
1.41%301.063.5%$311.78m
REGNRegeneron Pharmaceuticals, Inc.
0.93%422.522.6%$280.54m
VRTXVertex Pharmaceuticals Incorporated
1.48%185.761.9%$246.69m
ALXNAlexion Pharmaceuticals, Inc.
1.71%129.732.0%$214.36m
SRPTSarepta Therapeutics, Inc.
2.52%139.9815.4%$157.00m
AAgilent Technologies, Inc.
0.67%78.411.6%$155.05m
EXASExact Sciences Corporation
10.52%92.0425.3%$150.72m
INCYIncyte Corporation
1.82%84.852.5%$112.02m
ARRYArray BioPharma Inc.
2.33%23.248.2%$111.41m
NBIXNeurocrine Biosciences, Inc.
2.07%78.915.1%$80.47m
EXELExelixis, Inc.
1.41%21.526.4%$79.74m

Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.